Literature DB >> 23732037

Human papillomavirus testing in cervical cancer screening.

Philip E Castle1, Miriam Cremer.   

Abstract

Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23732037     DOI: 10.1016/j.ogc.2013.03.002

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  2 in total

1.  Cervical cancer screening with clinic-based Pap test versus home HPV test among Somali immigrant women in Minnesota: a pilot randomized controlled trial.

Authors:  Barrett Sewali; Kolawole S Okuyemi; Asli Askhir; Jerome Belinson; Rachel I Vogel; Anne Joseph; Rahel G Ghebre
Journal:  Cancer Med       Date:  2015-02-04       Impact factor: 4.452

2.  High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program.

Authors:  Hugo Sousa; Ana Tavares; Carla Campos; Joana Marinho-Dias; Margarida Brito; Rui Medeiros; Inês Baldaque; Cláudia Lobo; Luís Leça; Paula Monteiro; Fernando Tavares; Rui Henrique
Journal:  Papillomavirus Res       Date:  2019-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.